The in vivo Therapeutic Effect of Free Wanderer Powder (逍 遙 散 xiāo yáo sǎn, Xiaoyaosan) on Mice with 4T1 Cell Induced Breast Cancer Model

Anderson, 2002, The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis, Breast Cancer Research, 4, 197, 10.1186/bcr452 Aslakson, 1992, Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor, Cancer Research, 52, 1399 Bagchi, 2007, Men with breast cancer have high risk of second cancer, The Lancet Oncology, 8, 198, 10.1016/S1470-2045(07)70067-0 Bange, 2001, Molecular targets for breast cancer therapy and prevention, Nature Medicine, 7, 548, 10.1038/87872 Banka, 2006, Estrogen Induces Lung Metastasis through a Host Compartment–Specific Response, Cancer Research, 66, 3667, 10.1158/0008-5472.CAN-05-4416 Cory, 2002, The Bcl-2 family, regulators of cellular life-or-death switch, Nature Reviews Cancer, 2, 647, 10.1038/nrc883 Dy, 2004, Complementary and alternative medicine use by patients enrolled onto phase I clinical trials, Journal of Clinical Oncology, 22, 4810, 10.1200/JCO.2004.03.121 Emdadual, 2003, Apoptosis-inducing neurotoxicity of dopamine and its metabolites viareactive quinone generation in neuroblastoma cells, Biochimica et Biophysica Acta, 1619, 39, 10.1016/S0304-4165(02)00440-3 Ercoli, 1998, Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line, International Journal of Cancer, 76, 47, 10.1002/(SICI)1097-0215(19980330)76:1<47::AID-IJC9>3.0.CO;2-Y Fisher, 1998, Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, Journal of the National Cancer Institute, 90, 1371, 10.1093/jnci/90.18.1371 Fisher, 2005, Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, Journal of the National Cancer Institute, 97, 1652, 10.1093/jnci/dji372 Frenkel, 2005, Approach to communicating with patients about the use of nutritional supplements in cancer care, Southern Medical Journal, 98, 289, 10.1097/01.SMJ.0000154776.71057.E8 Jemal, 2003, Cancer Statistics, 2003, CA: A Cancer Journal for Clinicians, 53, 5 Jerry, 2000, A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development, Oncogene, 19, 1052, 10.1038/sj.onc.1203270 Jordan, 1994, Molecular mechanisms of antiestrogen action in breast cancer, Breast Cancer Research Treat, 31, 41, 10.1007/BF00689675 Lelekakis, 1999, A novel orthotopic model of breast cancer metastasis to bone, Clin Exp Metastasis, 17, 163, 10.1023/A:1006689719505 Nie, 2005, Progress of clinical application of Free Wanderer Powder, Journal of Shandong University of Traditional Chinese Medicine, 29, 327 Pati, 2004, Hormone-induced chromosomal instability in p53-null mammary epithelium, Cancer Research, 64, 5608, 10.1158/0008-5472.CAN-03-0629 Shi, 2004, The application of modified xiao yao san in the treatment of gynaecological disease, Journal of Chinese Medicine, 74, 25 Sivaraman, 2001, p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis, Proceedings of the National Academy of Sciences of the United States of America, 98, 12379, 10.1073/pnas.221459098 Wen, 2006, Clinical observation of the effect of modified Free Wanderer Powder on the adverse effect of chemotherapy after the breast cancer surgery, Journal of Traditional Chinese Medicine University of Hunan, 26, 38 Wyld, 1998, Endocrine aspect of the clinical management of the breast cancer-current issues, Endocrine-Related Cancer, 5, 97, 10.1677/erc.0.0050097 Xanthopoulos, 2005, Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination, Journal of Biomedicine and Biotechnology, 2005, 10, 10.1155/JBB.2005.10 Zhao, 2007, Anti-apoptosis effect of esculin on dopamine-induced cytotoxicity in the human neuroblastoma SH-SY5Y cell line, Neuropharmacology, 53, 724, 10.1016/j.neuropharm.2007.07.017